Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Chronic Pain - Pipeline Review, H1 2014

Published: Apr-2014 | Format: PDF | Global Markets Direct | Number of pages: 336 | Code: MRS - 1000

This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Pain
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Chronic Pain pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Chronic Pain
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Chronic Pain Overview 11
Therapeutics Development 12
Pipeline Products for Chronic Pain - Overview 12
Pipeline Products for Chronic Pain - Comparative Analysis 13
Chronic Pain - Therapeutics under Development by Companies 14
Chronic Pain - Therapeutics under Investigation by Universities/Institutes 20
Chronic Pain - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Chronic Pain - Products under Development by Companies 26
Chronic Pain - Products under Investigation by Universities/Institutes 34
Chronic Pain - Companies Involved in Therapeutics Development 35
DURECT Corporation 35
Johnson & Johnson 36
Allergan, Inc. 37
UMeWorld Limited 38
Sanofi 39
AstraZeneca PLC 40
Eli Lilly and Company 41
Nektar Therapeutics 42
Daiichi Sankyo Company, Limited 43
Merck & Co., Inc. 44
Santen Pharmaceutical Co., Ltd. 45
Daewoong Pharmaceutical Co., Ltd. 46
Laboratorios Del Dr. Esteve S.A. 47
Glenmark Pharmaceuticals Ltd. 48
Nippon Shinyaku Co., Ltd. 49
Orion Oyj 50
Pain Therapeutics, Inc. 51
Pfizer Inc. 52
Purdue Pharma L.P. 53
Teva Pharmaceutical Industries Limited 54
Collegium Pharmaceutical, Inc. 55
Benitec Biopharma Limited 56
Bionomics Limited 57
Acadia Pharmaceuticals Inc. 58
Elite Pharmaceuticals, Inc. 59
Zalicus Inc. 60
Hisamitsu Pharmaceutical Co., Inc. 61
Pozen, Inc. 62
Mertiva AB 63
tesa Labtec GmbH 64
Debiopharm International S.A. 65
Insys Therapeutics, Inc. 66
Chromocell Corporation 67
Immupharma Plc 68
Phosphagenics Limited 69
Grunenthal GmbH 70
CoLucid Pharmaceuticals, Inc. 71
Trevena, Inc. 72
Syntrix Biosystems, Inc. 73
Kineta, Inc. 74
Concert Pharmaceuticals, Inc. 75
QRxPharma Limited 76
Cara Therapeutics, Inc. 77
arGEN-X BV 78
Endo Pharmaceuticals Inc. 79
Sorrento Therapeutics, Inc. 80
Relmada Therapeutics, Inc. 81
Afferent Pharmaceuticals, Inc. 82
St. Charles Pharmaceuticals 83
Convergence Pharmaceuticals Ltd. 84
Adynxx, Inc. 85
Kareus Therapeutics, SA 86
Signature Therapeutics, Inc 87
Recro Pharma, Inc. 88
Creabilis SA 89
Neura Therapeutik, LLC 90
AbbVie Inc. 91
Nanomerics Ltd 92
ChironWells GmbH 93
Akron Molecules GmbH 94
GlobalAcorn 95
Chronic Pain - Therapeutics Assessment 96
Assessment by Monotherapy Products 96
Assessment by Combination Products 97
Assessment by Target 98
Assessment by Mechanism of Action 110
Assessment by Route of Administration 123
Assessment by Molecule Type 126
Drug Profiles 129
oxycodone ER - Drug Profile 129
(oxycodone hydrochloride + naloxone hydrochloride) - Drug Profile 131
fentanyl citrate - Drug Profile 133
celecoxib - Drug Profile 134
hydrocodone bitartrate ER - Drug Profile 136
(oxycodone + naltrexone) - Drug Profile 138
tapentadol hydrochloride - Drug Profile 140
duloxetine hydrochloride DR - Drug Profile 141
oxycodone hydrochloride ER - Drug Profile 143
buprenorphine hydrochloride - Drug Profile 144
tramadol hydrochloride SR - Drug Profile 146
hydrocodone bitartrate - Drug Profile 147
tapentadol hydrochloride ER - Drug Profile 148
(oxycodone hydrochloride + naltrexone hydrochloride) Extended Release - Drug Profile 151
PRC-062 - Drug Profile 153
sufentanil - Drug Profile 154
tapentadol hydrochloride - Drug Profile 156
(morphine + oxycodone) CR - Drug Profile 157
AGN-XX/YY - Drug Profile 159
cebranopadol - Drug Profile 160
onabotulinumtoxinA - Drug Profile 162
NKTR-181 - Drug Profile 164
sufentanil - Drug Profile 166
SAR-292833 - Drug Profile 167
dexmedetomidine hydrochloride - Drug Profile 168
DS-5565 - Drug Profile 170
CNV-2197944 - Drug Profile 171
dexmedetomidine - Drug Profile 173
(celecoxib + tramadol hydrochloride) - Drug Profile 174
E-52862 - Drug Profile 176
AYX-1 - Drug Profile 177
V-116517 - Drug Profile 178
bupivacaine - Drug Profile 179
resiniferatoxin - Drug Profile 181
PTI-202 - Drug Profile 182
hydromorphone - Drug Profile 183
hydrocodone bitartrate - Drug Profile 184
Debio-0827 - Drug Profile 185
PTI-721 - Drug Profile 186
oxycodone - Drug Profile 187
PA-65020 - Drug Profile 189
CR-845 - Drug Profile 190
PF-05089771 - Drug Profile 192
levorphanol tartrate ER - Drug Profile 194
CTP-354 - Drug Profile 195
PF-06273340 - Drug Profile 196
HS-731 - Drug Profile 197
oxymorphone hydrochloride - Drug Profile 198
TRV-734 - Drug Profile 199
PF-06372865 - Drug Profile 200
Drug to Activate mGlu2/3 for Chronic Pain - Drug Profile 201
AF-220 - Drug Profile 202
AF-221 - Drug Profile 203
oxymorphone - Drug Profile 204
DWJ-208 - Drug Profile 205
IPP-102199 - Drug Profile 206
CT-340 - Drug Profile 207
Kappa Opioid Receptor Biased Ligand Program - Drug Profile 208
RQ-00000008 - Drug Profile 209
GBR-900 - Drug Profile 210
CR-701 - Drug Profile 211
buprenorphine hydrochloride ER - Drug Profile 212
Z-212 - Drug Profile 213
ARX-8203 - Drug Profile 214
Small Molecule To Inhibit Cav2.2 Channel For Chronic Pain - Drug Profile 216
CNV-3000223 - Drug Profile 217
PFR-03088 - Drug Profile 218
PFR-06158 - Drug Profile 219
PF-6129 - Drug Profile 220
Conjugated Stigmine Program - Drug Profile 221
ddRNAi Program For Cancer-Associated Pain - Drug Profile 222
Small Molecule Agonising ER-Beta For Neurology And Pain - Drug Profile 224
Small Molecule To Inhibit ASK-1 For Chronic Pain - Drug Profile 225
Small Molecule To Inhibit mPGES-1 For Chronic Pain - Drug Profile 226
FY-101C - Drug Profile 227
Small Molecule To Inhibit GPR-84 For Chronic Pain - Drug Profile 228
grapiprant - Drug Profile 229
NE2 Endomorphin - Drug Profile 231
HS-731 - Drug Profile 232
DD-04107 - Drug Profile 233
Sodium Channel Blockers for Pain - Drug Profile 234
Small Molecule To Inhibit P2Y14 For Chronic Pain - Drug Profile 235
Prostatic Acid Phosphatase - Drug Profile 236
Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 237
NL-001 - Drug Profile 238
PFR-06177 - Drug Profile 239
PFR-03318 - Drug Profile 240
U-2902 - Drug Profile 241
CNV-3000164 - Drug Profile 242
A-836339 - Drug Profile 243
NL-002 - Drug Profile 244
fluticasone propionate - Drug Profile 245
CRB-0089 - Drug Profile 246
Small Molecules for Chronic Neuropathic Pain - Drug Profile 247
NET-END - Drug Profile 248
Drug For Chronic Pelvic Pain - Drug Profile 249
UMB-425 - Drug Profile 250
Mesenchymal Stem Cells - Drug Profile 251
CVIE - Drug Profile 252
PFR-03321 - Drug Profile 253
Small Molecules to Inhibit TRPA1 and TRPV1 for Pain - Drug Profile 254
Omnitram - Drug Profile 256
GA-8-SMOL-PAIN - Drug Profile 257
Small Molecules to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 258
SA-14867 - Drug Profile 259
TROX-1 - Drug Profile 260
BBI-11008 - Drug Profile 261
NM-0127 - Drug Profile 262
buprenorphine hydrochloride - Drug Profile 263
Small Molecules to Inhibit Cav2.2 Channel for Chronic Pain - Drug Profile 264
Small Molecules to Antagonize P2X3 for Chronic Pain - Drug Profile 265
SCP-1 - Drug Profile 266
CRB-0022 - Drug Profile 268
PFR-03325 - Drug Profile 269
Small Molecule To Inhibit Voltage-Gated Sodium Channel Type IX Alpha For Pain - Drug Profile 270
Drug to Block Nav 1.7 for Chronic And Neuropathic Pain - Drug Profile 271
Small Molecules Targeting Tyrosine Kinase Receptor A for Chronic Pain - Drug Profile 272
Ketamine Metabolites - Drug Profile 273
AKR-201 - Drug Profile 274
Monoclonal Antibodies Targeting Nav1.7 for Chronic Pain - Drug Profile 275
PFR-03323 - Drug Profile 276
Small Molecule to Inhibit TRPA1 for Chronic Pain - Drug Profile 277
Peptides for Chronic Pain - Drug Profile 278
GRT-6006 - Drug Profile 279
VLNX-4975 - Drug Profile 280
Chronic Pain - Recent Pipeline Updates 281
Chronic Pain - Dormant Projects 311
Chronic Pain - Discontinued Products 317
Chronic Pain - Product Development Milestones 319
Featured News & Press Releases 319

Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 327
Disclaimer 327

List of Tables

Number of Products under Development for Chronic Pain, H1 2014 21
Number of Products under Development for Chronic Pain - Comparative Analysis, H1 2014 22
Number of Products under Development by Companies, H1 2014 24
Number of Products under Development by Companies, H1 2014 (Contd..1) 25
Number of Products under Development by Companies, H1 2014 (Contd..2) 26
Number of Products under Development by Companies, H1 2014 (Contd..3) 27
Number of Products under Development by Companies, H1 2014 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2014 30
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Development, H1 2014 33
Comparative Analysis by Unknown Stage Development, H1 2014 34
Products under Development by Companies, H1 2014 35
Products under Development by Companies, H1 2014 (Contd..1) 36
Products under Development by Companies, H1 2014 (Contd..2) 37
Products under Development by Companies, H1 2014 (Contd..3) 38
Products under Development by Companies, H1 2014 (Contd..4) 39
Products under Development by Companies, H1 2014 (Contd..5) 40
Products under Development by Companies, H1 2014 (Contd..6) 41
Products under Development by Companies, H1 2014 (Contd..7) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Chronic Pain - Pipeline by DURECT Corporation, H1 2014 44
Chronic Pain - Pipeline by Johnson & Johnson, H1 2014 45
Chronic Pain - Pipeline by Allergan, Inc., H1 2014 46
Chronic Pain - Pipeline by UMeWorld Limited, H1 2014 47
Chronic Pain - Pipeline by Sanofi, H1 2014 48
Chronic Pain - Pipeline by AstraZeneca PLC, H1 2014 49
Chronic Pain - Pipeline by Eli Lilly and Company, H1 2014 50
Chronic Pain - Pipeline by Nektar Therapeutics, H1 2014 51
Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 52
Chronic Pain - Pipeline by Merck & Co., Inc., H1 2014 53
Chronic Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 54
Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 55
Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2014 56
Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 57
Chronic Pain - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 58
Chronic Pain - Pipeline by Orion Oyj, H1 2014 59
Chronic Pain - Pipeline by Pain Therapeutics, Inc., H1 2014 60
Chronic Pain - Pipeline by Pfizer Inc., H1 2014 61
Chronic Pain - Pipeline by Purdue Pharma L.P., H1 2014 62
Chronic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 63
Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H1 2014 64
Chronic Pain - Pipeline by Benitec Biopharma Limited, H1 2014 65
Chronic Pain - Pipeline by Bionomics Limited, H1 2014 66
Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 67
Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2014 68
Chronic Pain - Pipeline by Zalicus Inc., H1 2014 69
Chronic Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2014 70
Chronic Pain - Pipeline by Pozen, Inc., H1 2014 71
Chronic Pain - Pipeline by Mertiva AB, H1 2014 72
Chronic Pain - Pipeline by tesa Labtec GmbH, H1 2014 73
Chronic Pain - Pipeline by Debiopharm International S.A., H1 2014 74
Chronic Pain - Pipeline by Insys Therapeutics, Inc., H1 2014 75
Chronic Pain - Pipeline by Chromocell Corporation, H1 2014 76
Chronic Pain - Pipeline by Immupharma Plc, H1 2014 77
Chronic Pain - Pipeline by Phosphagenics Limited, H1 2014 78
Chronic Pain - Pipeline by Grunenthal GmbH, H1 2014 79
Chronic Pain - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2014 80
Chronic Pain - Pipeline by Trevena, Inc., H1 2014 81
Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H1 2014 82
Chronic Pain - Pipeline by Kineta, Inc., H1 2014 83
Chronic Pain - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 84
Chronic Pain - Pipeline by QRxPharma Limited, H1 2014 85
Chronic Pain - Pipeline by Cara Therapeutics, Inc., H1 2014 86
Chronic Pain - Pipeline by arGEN-X BV, H1 2014 87
Chronic Pain - Pipeline by Endo Pharmaceuticals Inc., H1 2014 88
Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2014 90
Chronic Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2014 91
Chronic Pain - Pipeline by St. Charles Pharmaceuticals, H1 2014 92
Chronic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H1 2014 93
Chronic Pain - Pipeline by Adynxx, Inc., H1 2014 94
Chronic Pain - Pipeline by Kareus Therapeutics, SA, H1 2014 95
Chronic Pain - Pipeline by Signature Therapeutics, Inc, H1 2014 96
Chronic Pain - Pipeline by Recro Pharma, Inc., H1 2014 97
Chronic Pain - Pipeline by Creabilis SA, H1 2014 98
Chronic Pain - Pipeline by Neura Therapeutik, LLC, H1 2014 99
Chronic Pain - Pipeline by AbbVie Inc., H1 2014 100
Chronic Pain - Pipeline by Nanomerics Ltd, H1 2014 101
Chronic Pain - Pipeline by ChironWells GmbH, H1 2014 102
Chronic Pain - Pipeline by Akron Molecules GmbH, H1 2014 103
Chronic Pain - Pipeline by GlobalAcorn, H1 2014 104
Assessment by Monotherapy Products, H1 2014 105
Assessment by Combination Products, H1 2014 106
Number of Products by Stage and Target, H1 2014 109
Number of Products by Stage and Mechanism of Action, H1 2014 121
Number of Products by Stage and Route of Administration, H1 2014 134
Number of Products by Stage and Molecule Type, H1 2014 137
Chronic Pain Therapeutics - Recent Pipeline Updates, H1 2014 289
Chronic Pain - Dormant Projects, H1 2014 319
Chronic Pain - Dormant Projects (Contd..1), H1 2014 320
Chronic Pain - Dormant Projects (Contd..2), H1 2014 321
Chronic Pain - Dormant Projects (Contd..3), H1 2014 322
Chronic Pain - Dormant Projects (Contd..4), H1 2014 323
Chronic Pain - Dormant Projects (Contd..5), H1 2014 324
Chronic Pain - Discontinued Products, H1 2014 325
Chronic Pain - Discontinued Products (Contd..1), H1 2014 326
List of Figures

Number of Products under Development for Chronic Pain, H1 2014 21
Number of Products under Development for Chronic Pain - Comparative Analysis, H1 2014 22
Number of Products under Development by Companies, H1 2014 23
Number of Products under Investigation by Universities/Institutes, H1 2014 29
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Products, H1 2014 33
Assessment by Monotherapy Products, H1 2014 105
Assessment by Combination Products, H1 2014 106
Number of Products by Top 10 Target, H1 2014 107
Number of Products by Stage and Top 10 Target, H1 2014 108
Number of Products by Top 10 Mechanism of Action, H1 2014 119
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 120
Number of Products by Top 10 Route of Administration, H1 2014 132
Number of Products by Stage and Top 10 Route of Administration, H1 2014 133
Number of Products by Top 10 Molecule Type, H1 2014 135
Number of Products by Stage and Top 10 Molecule Type, H1 2014 136

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing